Premium
Cytokine profile of autologous platelet‐derived eye drops in patients with ocular chronic graft‐versus‐host disease
Author(s) -
Valentini C. G.,
Nuzzolo E. R.,
Orlando N.,
Metafuni E.,
Bianchi M.,
Chiusolo P.,
Zini G.,
Teofili L.
Publication year - 2016
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12325
Subject(s) - chemokine , immunology , cytokine , platelet , medicine , graft versus host disease , eye drop , ophthalmology , disease , immune system , pathology
Ocular chronic GVHD is efficaciously treated with autologous platelet‐derived eye drops. We investigated the cytokine content of eye drops produced using a non‐gelified lysate obtained from autologous platelet‐rich plasma in six patients with ocular GVHD . In both the responding ( n = 4) and the resistant ( n = 2) patients, the eye drops were significantly enriched with various growth factors, in amounts proportional with the platelet counts. In contrast, chemokine ligand and interleukin levels were similar to those of plasma. The non‐responding patients showed the highest levels of chemokine (C‐X‐C motif) ligand ( CXCL )10. These findings provide possible explanations for beneficial or detrimental effects of eye drops.